Skip to main content
. 2022 Mar 8;15:17562848221080793. doi: 10.1177/17562848221080793

Figure 2.

Figure 2.

Kaplan–Meier curve for persistence of first-line infliximab and vedolizumab in moderate-to-severe UC.